Lipocine (LPCN)
(Delayed Data from NSDQ)
$5.95 USD
-0.46 (-7.18%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $6.07 +0.12 (2.02%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
Brokerage Reports
Lipocine Inc. [LPCN]
Reports for Purchase
Showing records 41 - 60 ( 106 total )
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
LPCN 1021''s Two Post-CRL Phase 3s Hit Primary Endpoints
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Q1 Reported; 1021?s Pivotal, Post-CRL Data in June, Sets up 1Q?18 PDUFA
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Dosing Study Readouts Next Month Should Right the Ship Ahead of Pre-Term Birth SPA
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Lipocine Inc.
Industry: Medical - Drugs
Dosing Study Enrollment Leaves First Oral Testosterone Approval on Tip of FDA''s Tongue
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Enrollment Complete in Two Post-CRL Studies; Data in June
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Q2 Dosing Studies Could Put 1021 Back in the Saddle
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Q4''16 Reported; Next Up- Oral TRT Ph3s in Q2; Reiterate Buy and $38PT
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.